Articles On Telix Pharmaceuticals (ASX:TLX)

The S&P/ASX 200 traded briefly above 7000 after oil fell to a six-month low and upbeat US economic data soothed global recession worries. The Australian benchmark touched a seven-week high of 7021 before shaving its advance to 12 poi...

The S&P/ASX 200 Index (ASX: XJO) defied its earlier downturn to close higher after the Reserve Bank of Australia (RBA) lifted interest rates for a fourth consecutive month. The index was 0.07% higher at 6,998.10 points at Tuesday’s c...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has fought back and is edging slightly higher. At the time of writing, the benchmark index is up to 6,994.9 points. Four ASX shares that are climbing more than most today are listed...

ShareCafeLunch Report: 2 August, 2022 by Paul Sanger   The Reserve Bank of Australia is expected to hike by 50 basis points after official data showed prices in Australia rose 6.1 per cent in the second quarter compared with a year ago. At...

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (A...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

In times of great uncertainty the Australian healthcare sector can offer investors plenty of choice, with varying degrees of risk and opportunities. -Australia’s healthcare sector has seen record government investment-Global pandemic has ac...

After a wobbly start to the day, the S&P/ASX 200 Index (ASX: XJO) posted a gain for the first time in three sessions after lacklustre performances yesterday and on Friday. At the end of Tuesday’s trade, the index was up 0.26% at 6,...

The share market logged its best week since March as a six-week high on Wall Street bolstered confidence this year’s market rout may be easing.   The S&P/ASX 200 eased three points or 0.04 per cent today, falling narrowly short of a...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.1% to 6,800.9 points. Four ASX shares that are climbing more than most today are listed bel...

ShareCafeLunch Report: 22 July, 2022 by Paul Sanger   The S&P/ASX 200 traded flat by midday in Sydney after spending much of the morning in negative territory. The benchmark erased early losses after opening 0.5 per cent lower and brief...

Australian shares gained momentum late morning, rising for a third session despite weak earnings from social media giant Snap weighing on US futures. The S&P/ASX 200 overcame early weakness to reach the halfway mark 16 points or 0.24...

ShareCafeEvening Report: 21 July, 2022 by Paul Sanger   At the closing bell, the S&P/ASX 200 was 0.52 per cent or 35.10 points higher at 6794.30. The lithium and green metals sector was on fire today, after electric vehicle maker Tesla...

ASX closes 0.30% higher after being in the red Lithium stocks rise on Tesla guidance Woodside down despite bumper revenue After trading in red for most of the day, the ASX 200 finished Thursday 0.40 higher at 6,784. Energy stocks dragged...

A late rally lifted the Australian share market to its strongest close in five weeks as strength in bank and tech stocks outweighed pressure on iron ore miners after China established a steelmakers’ purchasing cartel. The S&P/ASX 200...

Melbourne-based Telix Pharmaceuticals says it made $19.3m in just 10 weeks after beginning US sales of its new prostate cancer diagnostic imaging agent.

Telix Pharmaceuticals (TLX) reports more than a ten-fold quarter-on-quarter revenue increase for the three months ending June 30 The healthcare company received $22.5 million in total revenue which reflects sales of its prostate cancer ima...

The share market hovered near a three-week high as declines in resource stocks outweighed gains in growth sectors. The S&P/ASX 200 eased five points or 0.07 per cent by lunchtime. The Australian benchmark struggled for direction afte...

ShareCafeLunch Report: 21 July, 2022 by Paul Sanger   Australian shares are little changed in mixed trading this morning. At noon, the S&P/ASX 200 is 0.05 per cent or 3.60 points lower at 6755.60. Australian lithium and nickel companies...

ShareCafeStocks of the Hour: 21 July, 2022                  Orthocell (ASX:OCC) recently signed a global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc, one of the largest dental implant companies in...

At lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. The benchmark index is currently down 0.1% to 6,754.1 points. Here’s what is happening on the ASX 200 today: ANZ shares edge lower The Au...

21 Jul 2022 - A snapshot of the stocks on the move featuring Orthocell (ASX:OCC), Telix Pharmaceuticals (ASX:TLX) and Asra Minerals (ASX:ASR).

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is pushing higher in trade today. At the time of writing, the share is trading more than 11% in the green at $6.21 apiece. Investors are bidding up the Telix share price following t...

Highlights: ASX 200 stocks opened a little lower today, however, the benchmark index recovered a bit and started trading flat after a while. The market has been taking cues from the Wall Street that ended lower in its last session thou...

MELBOURNE, Australia, July 21, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2...

Mach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after device submission for FebriDX rejected by US FDA Three companies announce major milestones in clinical trials Healthcare and life sciences e...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

ASX biotech shares were hammered in FY22 with the sector facing heavy losses, in line with the wider technology sector. The ETFs S&P Biotech ETF (ASX: CURE), an index fund tracking the global biotech sector, is down almost 24% this y...

Telix Pharmaceuticals (ASX:TLX) has announced the appointment of a CEO for its Americas business and dosed the final patient and completed recruitment into the pivotal Phase 3 study, ZIRCON.

Telix Pharmaceuticals (TLX) appoints Kevin Richardson to the role of CEO Telix Americas The senior global executive will step into the position from today, bringing with him 25 years of experience in the healthcare industry Dr Christian Be...

Lumos’ FebriDX was rejected by the FDA Hexima hurt by unexpected readout from Phase 2 trial Anteris reports good progress on DurAVR study Some unexpected news have driven a couple ASX healthcare stocks down by double digits this morning....

ShareCafeLunch Report: 11 July, 2022 by Melissa Darmawan   The fall in materials and information tech led the retreat on the Australian sharemarket as gains in energy and financial stocks weren’t enough to offset the decline. At noon, the S...

MELBOURNE, Australia, July 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zircon...

MELBOURNE and INDIANAPOLIS, July 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that Kevin Richardson, a senior global executive with a career focus on sales, marketing and bus...

This month I’ve been looking at a number of shares that Bell Potter has rated as its top picks for FY 2023. You can read about its tech picks here and its energy picks here. On this occasion, let’s take a look at a couple of ASX health...

Telix Pharmaceuticals (TLX) signs a licence and distribution agreement with Isologic Innovative Pharmaceuticals for its investigational prostate cancer imaging agent Illuccix Under the agreement, Isologic will be the commercial distributor...

Aussie shares sank to their lowest level since November 2020 as recession fears continued to batter financial markets. The S&P/ASX 200 dived 136 points or 2.07 per cent towards a sixth straight loss. Barring a miraculous afternoon re...

MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging...

MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging...

Telix Pharmaceuticals (ASX:TLX) and US-based RefleXion Medical have signed a new co-development and commercialisation agreement.

MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga...

MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-dev...

ShareCafeLunch Report: 10 June, 2022 by Lauren Evans   The Aussie sharemarket is off to another weak start following a red finish on Wall Street. Australian shares are on track for their largest weekly decline this year as markets digest th...

Telix Pharmaceuticals (TLX) signs a partnership for prostate cancer treatment with RefleXion Medical The parties agreed to sign a co-development and commercialisation agreement to expand the use of Telix’s prostate cancer imaging agent Ill...

10 Jun 2022 - A snapshot of the stocks on the move featuring Bubs Australia (ASX:BUB), Telix Pharmaceuticals (ASX:TLX), Terracom (ASX:TER) & Medallion Metals (ASX:MM8).

Telix Pharma’s Illucix could be used in BgRT radiotherapies in the US Chimeric Therapeutics advances its CAR T therapy program Telix expands partnership with US-based RefleXion Telix Pharma (ASX:TLX) has expanded its partnership with Cali...

Telix Pharmaceuticals (ASX:TLX) has received a $17.25 million R&D tax refund from the federal government for eligible activities undertaken in the year ended 31 December 2021.

MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic pr...

ShareCafeEvening Report: 7 June, 2022 by Melissa Darmawan   The cost of living is set to rise after the Reserve Bank of Australia (RBA) raised the cash rate by 50 basis points versus the expected 40, sending the ASX 200 to a three week low,...